Researchers have discovered a cellular pathway that promotes inflammation in diseases like asthma, rheumatoid arthritis, and psoriasis. Understanding this pathway may provide opportunities for tailored treatments of inflammatory and autoimmune diseases.
The Cleveland Clinic has received a significant grant to establish a new chair in Preventive Cardiology. Dr. Stanley Hazen will be the first holder of the Leonard Krieger Chair, focusing on developing an inhibitor for treating atherosclerosis through research on gut flora pathways.
A specific genetic alteration has been identified in epithelioid hemangioendothelioma (EHE), a rare but devastating vascular cancer. A new diagnostic test for EHE has also been developed using this finding.
A Cleveland Clinic researcher has received a $1.1 million grant to investigate why females are disproportionately affected by lupus. The study will explore the role of immunosuppressive cells in the development of the disease and its impact on males.
Navitoclax, a new drug in early clinical testing, offers hope for treating chronic leukemia by identifying patients who will respond. Researchers discovered new markers that can predict which patients will benefit from the treatment.
Researchers have identified genetic mutations in patients with Barrett's esophagus and esophageal adenocarcinoma, linking a heritable cause to the disease. Three genes, MSR1, ASCC1, and CTHRC1, were found to be mutated in 11% of BE/EAC patients, suggesting a significant genetic predisposition.
Researchers at Cleveland Clinic have identified a molecular pathway that promotes brain tumor growth in malignant glioma. The study found that existing medications block this pathway and delay tumor growth in animal models, suggesting a potential new treatment option.
Researchers identified a genetic mutation causing fatal developmental disease MOPD1, affecting fetal growth and brain development. The mutation is prevalent in the Ohio Amish population, with approximately 6% prevalence.
A new study discovered that specific intestinal microflora metabolize phosphatidyl choline, a common dietary lipid found in animal products, into compounds associated with increased cardiovascular disease risk. The study found that higher levels of these compounds are linked to an increased risk of heart attack, stroke, and death.
Stark's contributions span biochemistry, gene regulation and cell signaling, influencing immunity and cancer research. He is recognized for developing Northern and Western techniques widely used in research and clinical applications.
A newly discovered biological pathway transforms normal cells into aggressive tumors by regulating the epithelial-mesenchymal transition (EMT) process. This mechanism involves a specific molecular factor called hnRNP E1, which can be used as a diagnostic approach for cancer.
Researchers at Cleveland Clinic's Lerner Research Institute found that combining resveratrol with rapamycin suppresses tumor growth in breast cancer cells. Resveratrol, a compound in red wine, mitigates rapamycin-induced resistance and promotes anti-tumor activity.
A new diagnostic scoring system improves on established criteria for identifying individuals with genetic mutations of the tumor suppressor gene PTEN. The system offers more accurate diagnoses, guide to genetic testing, and personalized cancer screening.
The study reveals KILLIN as a novel predisposition gene for Cowden syndrome and Cowden-like syndrome, allowing for earlier diagnosis of tumors. Individuals with classic Cowden syndrome should be offered PTEN testing first, followed by screening for the inactivated KILLIN gene.
A recent Cleveland Clinic study found a three-fold increase in gelatinase activity among patients with brain aneurysms, weakening the structural proteins in brain arteries. This discovery could lead to the development of a predictive test and preventive therapy for aneurysm formation.